PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 54 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $755,411 | -14.1% | 244,470 | +25.2% | 0.00% | – |
| Q2 2023 | $878,968 | +8.9% | 195,326 | +37.9% | 0.00% | – |
| Q1 2023 | $807,474 | +48.6% | 141,662 | +57.5% | 0.00% | – |
| Q4 2022 | $543,291 | -53.8% | 89,949 | -49.4% | 0.00% | – |
| Q3 2022 | $1,175,000 | -53.2% | 177,788 | -63.0% | 0.00% | – |
| Q2 2022 | $2,510,000 | -33.4% | 480,788 | -12.0% | 0.00% | -100.0% |
| Q1 2022 | $3,770,000 | -64.2% | 546,475 | -35.4% | 0.00% | 0.0% |
| Q4 2021 | $10,528,000 | -55.5% | 845,714 | +11.8% | 0.00% | -66.7% |
| Q3 2021 | $23,650,000 | +525.2% | 756,787 | +472.6% | 0.00% | – |
| Q2 2021 | $3,783,000 | +262.4% | 132,165 | +449.0% | 0.00% | – |
| Q1 2021 | $1,044,000 | -46.2% | 24,074 | -11.3% | 0.00% | – |
| Q4 2020 | $1,941,000 | +390.2% | 27,128 | +106.2% | 0.00% | – |
| Q3 2020 | $396,000 | – | 13,155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $287,436,000 | 2.91% |
| Baker Brothers Advisors | 10,123,824 | $289,845,000 | 1.27% |
| Logos Global Management LP | 400,000 | $11,452,000 | 0.96% |
| Rock Springs Capital Management LP | 382,359 | $10,947,000 | 0.22% |
| HHLR ADVISORS, LTD. | 583,333 | $16,701,000 | 0.17% |
| Virtus ETF Advisers LLC | 6,622 | $190,000 | 0.08% |
| Jump Financial, LLC | 13,700 | $392,000 | 0.04% |
| ARS Investment Partners, LLC | 7,400 | $212,000 | 0.02% |
| FEDERATED HERMES, INC. | 336,100 | $9,623,000 | 0.02% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 1,287,735 | $36,867,853,000 | 0.02% |